4basebio (LON:4BB – Get Free Report) released its quarterly earnings data on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
4basebio Stock Down 0.5%
Shares of LON 4BB traded down GBX 2.70 during trading hours on Tuesday, hitting GBX 559.80. 261 shares of the stock were exchanged, compared to its average volume of 1,353. 4basebio has a 12 month low of GBX 420 and a 12 month high of GBX 820. The firm has a fifty day moving average price of GBX 511.05 and a 200-day moving average price of GBX 510.01. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market cap of £86.69 million, a PE ratio of -5.14 and a beta of 1.09.
Analyst Upgrades and Downgrades
Separately, Royal Bank Of Canada decreased their target price on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of GBX 1,400.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Read More
- Five stocks we like better than 4basebio
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
